July 6, 2026
The BPC-157 + TB-500 Recovery Stack: What It Is and How to Track It
The most-discussed repair-peptide combination, explained: the rationale behind pairing them, the research-compound caveats, and how to log the stack without muddying your data.
If you follow injury-recovery discussions, you have seen "BPC-157 and TB-500" recommended together for stubborn soft-tissue issues. It is the recovery world's most famous stack — sometimes nicknamed the "wolverine stack." Here is what it actually is, the important caveats, and how to track it cleanly.
The two compounds
| Peptide | Proposed role | Notes |
|---|---|---|
| BPC-157 | Angiogenic; supports blood-vessel formation and gut/tissue repair in animal studies | Research compound; not approved for human use |
| TB-500 (thymosin beta-4 fragment) | Affects actin and cell migration; studied for tissue repair | Research compound; not approved for human use |
The pairing rationale is complementary pathways: BPC-157 is associated with new blood-vessel formation, while TB-500 is associated with cell migration and structural repair. The community theory is that together they address different steps of the same healing process.
The caveat that has to come first
Both BPC-157 and TB-500 are research compounds. The supportive evidence is largely from animal models, and neither is an approved human medicine. Human safety and efficacy data are limited. Nothing here is an endorsement — it is an explanation of a widely discussed protocol so that people who choose to track it can do so accurately.
How the stack is typically discussed
In community protocols, BPC-157 is often dosed daily (sometimes split), while TB-500 is dosed less frequently because of its longer proposed activity — a common pattern is a higher-frequency BPC schedule alongside a once- or twice-weekly TB-500 schedule, often localized near the injury for BPC. Specific numbers vary widely and are not standardized, which is exactly why logging matters.
The tracking problem with any stack
The core difficulty: if you start two compounds at once and something changes — good or bad — you cannot attribute it. Cleaner practice:
- Stagger the starts where possible — introduce one, then the other a week later, so an early side effect has a clear owner.
- Log each compound separately — dose, site, and frequency per compound, never as a merged "stack" entry.
- Log side effects per compound, with timing.
- Define your outcome up front — pain-free range of motion, a specific movement, a return-to-activity date. Track that, not vibes.
What to record
- Compound, dose, and injection site (BPC is often injected near the target area — record where).
- Frequency and the exact days.
- Supplier batch, if you rotate sources.
- A simple daily recovery score for the injured area.
- Any systemic side effects, tied to the specific compound.
Reading the data
Because soft-tissue healing is slow, judge the stack over weeks, not days, and against your predefined outcome. A recovery log that shows a steady improvement in range of motion over six weeks is far more informative than a memory of "I think it helped."
TrackPep supports multiple active compounds with independent dose logs and a body-map for injection sites, so a BPC-157 + TB-500 protocol stays two clear data streams instead of one blur.
Educational only — not medical advice. BPC-157 and TB-500 are research compounds, not approved medicines. Consult a licensed healthcare provider before use.